Other

Dyonics, Inc.

Smith + Nephew

Newtonics Spectra Inc.

Lanny L Johnson

Leonard J Bonnell

Donald W Garnett

Suganda Jutamulia

Douglas D Sjostrom

Benny L Chan

Chih Yen Liu

Robert E Brissette

Edward H McHugh

In embodiments, a method of treating a disease or condition caused by an enveloped virus in a mammal is disclosed including administering to the mammal a composition comprising protocatechuic acid crystals and disrupting the viral envelope of the enveloped virus. The mammal may be a human. The composition may include a pharmaceutically acceptable carrier. The enveloped virus may be a coronavirus. The enveloped virus may be a virus of the family Orthomyxoviridae.

Methods and compositions including protocatechuic acid crystals for the treatment of conditions caused by an enveloped virus

The present disclosure describes a prophylactic method for the prevention of injury or disease of a synovial joint in a mammal that includes orally administering a composition including protocatechuic acid and a pharmaceutically acceptable carrier. The composition includes at least 0.035 mmol protocatechuic acid per kilogram bodyweight of the mammal. The orally administered composition increases insulin-like growth factor-1 (IGF-1) in the synovial fluid of a synovial joint of the mammal. The administration of the compound also increases insulin-like growth factor-1 (IGF-1) in the bloodstream of the mammal.

Methods of oral administration of protocatechuic acid for treating or reducing the severity of a joint injury or disease

This disclosure provides a method of treating an infection or inflammation of an eye of a mammal including contacting an eye with a solution comprising sterilized water and protocatechuic acid. The protocatechuic acid may be between about 0.01 wt % and 1.25 wt % in the solution. The solution may include saline. The solution may include ciprofloxacin and/or norfloxacin. This disclosure further provides a method of disinfecting a contact lens including contacting a contact lens with a solution including protocatechuic acid. The solution may include a surfactant. The surfactant may include polyethylene glycol esters of fatty acids, coconut, polysorbate, polyoxyethylene or polyoxypropylene ethers of high alkanes C12-C18. The surfactant may include poly(oxypropylene)-poly(oxyethylene) adducts of ethylene diamine having a molecular weight about 7,500 to about 27,000 wherein at least about 40 weight percent of the adducts is poly(oxyethylene).

Eye wash compositions and methods

The disclosure provides a method of joint repair or replacement in a mammal including surgically debriding a joint, administering a composition including a therapeutically effective amount of protocatechuic acid for between about 1 day and 1 month prior to arthroscopically debriding the joint, and administering the composition for between 1 day and 6 months after arthroscopically debriding the joint. The administration of the composition may be through oral administration. The composition may be a tablet, a pill, or a capsule. The tablet, the pill, or the capsule may include about 500 mg of protocatechuic acid.

Biological total joint replacement

The disclosure is directed to a beverage sachet including a powder which includes protocatechuic acid, an electrolyte, and a sweetener. The sachet can further include a cannabinoid. The cannabinoid may be cannabidiol. The electrolyte may include sodium chloride salt or monopotassium phosphate salt. The sachet may further include vitamin C, vitamin D, a B vitamin, magnesium, or calcium. The sweetener may include sucrose, glucose, dextrose, maltodextrins, or fructose. The disclosure also includes a beverage including protocatechuic acid and a cannabinoid. The cannabinoid may be cannabidiol. The beverage may be a sports beverage including sweeteners and electrolytes. The beverage may be a health beverage including a fruit, a vegetable, vitamin C, vitamin D, a B vitamin, magnesium, or calcium.

Compositions including a cannabinoid and protocatechuic acid

In embodiments, a method of treating a disease or condition caused by Respiratory Syncytial Virus in a mammal is disclosed including administering to the mammal a composition comprising protocatechuic acid crystals. The mammal may be a human. The composition may include a pharmaceutically acceptable carrier.

Methods and compositions including protocatechuic acid crystals for the treatment of respiratory syncytial virus

This disclosure provides methods for diagnosing a cognitive disorder including performing a tactile perception test on a subject, measuring the subject's tactile perception test performance with a microelectromechanical sensor, and performing a cognitive disorder diagnosis on the subject. The tactile perception test may include distinguishing between various shaped and sized objects and selecting a predetermined one. The tactile perception test may include a two-point discrimination test. The tactile perception test may include testing lower extremity coordination. The tactile perception test may include testing upper extremity coordination. The cognitive disorder may include dementia, Alzheimer's, brain trauma, or concussion. The microelectromechanical sensor may include an accelerometer or gyroscope.

Methods and systems for diagnosing cognitive conditions

A composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid is provided. The disclosure further provides a method of treating inflammation comprising administering a composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid to a patient in need thereof. The disclosure further provides a method of treating inflammation including administering a composition including protocatechuic acid and a composition including a cannabinoid to a patient in need thereof. In embodiments, the composition including protocatechuic acid and the composition including a cannabinoid may be administered simultaneously within about 60 minutes of each other. In embodiments, the cannabinoid includes Cannabidiol (CBD).

A method of disinfectingis disclosed including treating a surface with a solution comprising 3,4-Dihydroxybenzoic acid ethyl ester. The solution may further include protocatechuic acid. The solution may include an alcohol. The alcohol may include methanol, ethanol, or isopropyl alcohol. The surface may include a solid surface, a porous or semi-porous surface, or a cloth-like surface. The surface may include a surface on skin, clothes, masks, a medical device, food processing equipment, hearing aid or a surgical implant. The surface may include a surface in a healthcare facility.

disinfectant

This disclosure is directed to methods of using compositions comprising protocatechuic acid (PCA) to kill virus including a Covid-19 virus. The compositions generally comprise protocatechuic acid, a liquid vehicle, and a stabilizer. In embodiments, the liquid vehicle comprises an alcohol and/or water. In preferred embodiments, the oil is an essential oil. In embodiments, the compositions may comprise principally protocatechuic acid, liquid vehicle, and stabilizer as the main ingredients. The compositions may be sprayed onto various products and articles of manufacture, and mammalian and human skin, to kill virus including a Covid-19 virus and to further protect the product or human skin for a period of time up to 24 hours or more. In preferred embodiments, an alcohol component kills virus on contact, and after drying, the residual surface PCA coating provides a continuing anti-viral function.

Compositions comprising protocatechuic acid and methods of use

A sensitivity enhancement wearable having at least one aperture possessing unique attributes so that a sensitivity enhanced region of a body extends through the aperture thereby creating increased sensitivity in the sensitivity enhanced region.

Sensitivity enhancement wearable

This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth, including killing bacterial biofilms.

Antimicrobials and methods of use thereof

The present disclosure provides methods for killing the SARS CoV-2 virus in mammals and treating the Coronavirus Disease-19 (Covid-19) in mammals including humans using compositions including protocatechuic acid. The present disclosure provides methods and pharmaceutical and nutraceutical compositions that reduce or substantially eliminate the SARS CoV-2 virus in mammals. In one embodiment, a method of treating a mammal with Covid-19 is provided comprising administering protocatechuic acid to a mammal in need of such treatment a therapeutically effective amount of a protocatechuic acid composition.

Growing community of inventors

Okemos, MI, United States of America

Lanny L Johnson